stockrowTarsus Pharmaceuticals, Inc.
TARS Healthcare Biotechnology
Tarsus Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $451.4 million, up 146.7% from fiscal 2024.
- Revenue
- +63.9%
- EPS
- −4,699.1%
- Free cash flow
- −144.1%
- Total debt
- +0.90%
Quarter to September 2026, against a year earlier
Follow TARS
Alert me
Tarsus Pharmaceuticals, Inc. (TARS) Current ratio
Tarsus Pharmaceuticals, Inc.'s current ratio at the end of the quarter to 30 September 2026 was 2.0×, down 1.9× from fiscal 2025 (3.9×). Over the past ten years it has ranged from 3.9× (fiscal 2025) to 70.9× (fiscal 2019) — the current reading is the lowest in ten years. That is below the Biotechnology industry median of 4.9× and below the Healthcare sector median of 3.1×.
Current ratio, annual
Embed this chart
Annual newest first
| Period | Current ratio | Change |
|---|---|---|
| FY2025 | 3.9× | (12.94%) |
| FY2024 | 4.4× | (36.19%) |
| FY2023 | 6.9× | (52.53%) |
| FY2022 | 14.6× | (4.71%) |
| FY2021 | 15.3× | (51.61%) |
| FY2020 | 31.7× | (55.29%) |
| FY2019 | 70.9× | 432.23% |
| FY2018 | 13.3× | — |
Quarterly newest first
| Period | Current ratio | Change |
|---|---|---|
| Sep 2026 | 2.0× | (38.67%) |
| Jun 2026 | 3.2× | (14.58%) |
| Mar 2026 | 3.7× | (2.83%) |
| Dec 2025 | 3.9× | (10.12%) |
| 22 more quarters | Free account |
Against its own ten years
Current ratio against peers
| Company | Current ratio |
|---|---|
| ELVN Enliven Therapeutics, Inc. compare | 64.1× |
| VRDN Viridian Therapeutics, Inc. compare | 14.5× |
| DYN Dyne Therapeutics, Inc. compare | 12.0× |
| CELC Celcuity, Inc. compare | 8.9× |
| VKTX Viking Therapeutics, Inc. compare | 7.3× |
| DNLI Denali Therapeutics Inc. compare | 6.2× |
| ACAD ACADIA Pharmaceuticals Inc. compare | 3.8× |
| TLX Telix Pharmaceuticals Limited compare | 2.0× |
| TARS Tarsus Pharmaceuticals, Inc. | 2.0× |
| Biotechnology industry median | 4.9× |
| Healthcare sector median | 3.1× |
| Market median | 1.6× |
What Current ratio is
Current Ratio shows whether a company’s short-term assets are enough to cover the bills and debts it must pay within the next year.
Current Assets (Total) ÷ Current Liabilities (Total)
More on TARS
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement